Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Key Highlights
- ➤Lorundrostat cut placebo-adjusted SBP 9.6 mmHg in CKD at week 12
- ➤Lorundrostat reduced CKD participant UACR 52.2% versus placebo at week 12
- ➤Target SBP below 130 mmHg reached by 44% with CKD versus 18% placebo
- ➤FDA review ongoing; PDUFA target date is December 22, 2026
- ➤Confirmed hyperkalemia rates were 2.4% in CKD and 0% without CKD
Expert Statements
Liffert Vogt, Professor of Clinical Nephrology and Renal Physiology at Amsterdam University Medical Center and the University of Amsterdam
“These results are encouraging. Besides impacting blood pressure in participants with and without kidney disease, treatment with lorundrostat showed a meaningful reduction in albuminuria, a key marker for cardiovascular and kidney risk control.”
Liffert Vogt, Professor of Clinical Nephrology and Renal Physiology at Amsterdam University Medical Center and the University of Amsterdam
“In patients with chronic kidney disease, high blood pressure and albuminuria are two of the most important risk factors we can modify, and lorundrostat improved both in this trial.”
Terry Ferguson, Chief Medical Officer of Mineralys Therapeutics
“CKD affects approximately 37 million adults in the U.S., and up to 75% of patients with CKD have uncontrolled hypertension. Aldosterone is a common driver of both hypertension and CKD, and lorundrostat is designed to reduce aldosterone at the source.”
Terry Ferguson, Chief Medical Officer of Mineralys Therapeutics
“In Launch-HTN, lorundrostat provided similar blood pressure reductions in participants with or without CKD, and it not only did so across a broad spectrum of the disease, but it did it in a way that reduced albuminuria.”
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD
In participants with CKD, lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD
Get started
Create a free account to read the full story.